Patents by Inventor Brent Iverson

Brent Iverson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Directed evolution of enzymes and antibodies
    Publication number: 20030036092
    Abstract: The invention relates to methods of selecting proteins, out of large libraries, having desirable characteristics. Exemplified are methods of expressing enzymes and antibodies on the surface of host cells and selecting for desired activities. These methods have the advantage of speed and ease of operation when compared with current methods. They also provide, without additional cloning, a source of significant quantities of the protein of interest.
    Type: Application
    Filed: February 12, 2001
    Publication date: February 20, 2003
    Applicant: Board of Regents, The University of Texas System
    Inventors: Brent Iverson, George Georgiou, Gang Chen, Mark J. Olsen, Patrick S. Daugherty
  • Chromophore probe for detection of nucleic acid
    Patent number: 5595726
    Abstract: The present invention is directed to chromophoric probes for use in detecting nucleic acid sequences. More particularly, the invention is directed to probes that comprise a texaphyrin chromophore molecule covalently coupled or conjugated to a site-directing molecule, the site-directing molecule having affinity for a biological receptor or a nucleic acid sequence. In one embodiment of the invention, the probe comprises a texaphyrin chromophore conjugated to an oligonucleotide having complementary binding affinity for a target nucleic acid sequence.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 21, 1997
    Assignees: Pharmacyclics, Inc., Board of Trustees, Univ. of TX Sys.
    Inventors: Darren Magda, Jonathan L. Sessler, Brent Iverson
  • Texaphyrins and uses thereof
    Patent number: 5567687
    Abstract: A texaphyrin having substituents containing ethoxy groups, methods for using texaphyrins in photodynamic therapy, and cleavage of a polymer of deoxyribonucleic acid are disclosed. The in vivo treatment of tumors and atheroma is demonstrated using Lu(III)texaphyrin complexes. A preferred method of use is the site-specific cleavage of a polymer of deoxyribonucleic acid and a preferred texaphyrin is a derivatized texaphyrin having binding specificity, in particular, a texaphyrin covalently coupled to a site-directing molecule, preferably an oligonucleotide.
    Type: Grant
    Filed: September 21, 1994
    Date of Patent: October 22, 1996
    Assignees: University of Texas, Pharmacyclics, Inc.
    Inventors: Darren Magda, Jonathan L. Sessler, Brent Iverson, Petra L. Jansen, Meredith Wright, Tarak D. Mody, Gregory W. Hemmi
  • Texaphyrin metal complex mediated ester hydrolysis
    Patent number: 5559207
    Abstract: A method of phosphate ester hydrolysis including incubating a solution of an aqueous phosphate ester with a texaphyrin metal complex. The metal is a metal cation having catalytic activity for ester bond hydrolysis in aqueous solution, in particular, a lanthanide metal cation, preferably Eu(III) or Dy(III). A preferred substrate is RNA and a preferred texaphyrin is a derivatized texaphyrin having binding specificity, in particular, a texaphyrin covalently coupled to a site-directed molecule, preferably an oligonucleotide.
    Type: Grant
    Filed: April 14, 1994
    Date of Patent: September 24, 1996
    Assignees: Board of Regents, University of Texas, Pharmacyclics, Inc.
    Inventors: Jonathan L. Sessler, Daniel A. Smith, Richard A. Miller, Kevin L. Ross, Meredith Wright, William C. Dow, Vladimir A. Kr al, Brent Iverson, Darren Magda